Concord Biotech Ltd
NSE:CONCORDBIO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 253.1
2 601.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Concord Biotech Ltd
Total Current Liabilities
Concord Biotech Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Concord Biotech Ltd
NSE:CONCORDBIO
|
Total Current Liabilities
₹1.4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Total Current Liabilities
₹95.9B
|
CAGR 3-Years
6%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Total Current Liabilities
₹54.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Total Current Liabilities
₹172.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
16%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Total Current Liabilities
₹48.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Total Current Liabilities
₹21.2B
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Concord Biotech Ltd
Glance View
Concord Biotech Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2023-08-18. Concord Biotech Limited is an India-based research and development driven biopharma company. The firm is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The firm manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. The company manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. The company also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The firm provides products in the critical care, immunology, nephrology, and transplant medicine segments.
See Also
What is Concord Biotech Ltd's Total Current Liabilities?
Total Current Liabilities
1.4B
INR
Based on the financial report for Mar 31, 2024, Concord Biotech Ltd's Total Current Liabilities amounts to 1.4B INR.
What is Concord Biotech Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
10%
Over the last year, the Total Current Liabilities growth was -26%. The average annual Total Current Liabilities growth rates for Concord Biotech Ltd have been 10% over the past three years .
You don't have any saved screeners yet
